#Deep dive
Long-form pieces over 2,000 words.
Semaglutide and MASH: what ESSENCE found
Semaglutide has a licensed indication for MASH, the inflamed form of fatty liver disease. Here is what the ESSENCE trial showed, and what it has not.
GLP-1 and GIP: a short incretin history
Incretins went from a failed 1906 diabetes experiment to GLP-1 and GIP drugs. Here are the dates, the discoveries, and where the evidence thins out.
Tirzepatide history: discovery to approval
Six milestones trace how tirzepatide went from a laboratory dual-agonist hypothesis in 2018 to one of the most-studied prescription medicines in the world.
Tesamorelin: from discovery to FDA approval
How tesamorelin moved from a lab compound to FDA approval in 2010, and why the European application was withdrawn in 2012.
A short history of TB-500
TB-500 (thymosin beta-4) was first sequenced in 1981. Four decades on, it has no approved human use and only one controlled trial, in eye disease.
Semax: from 1991 lab bench to today
Semax is licensed in Russia for stroke recovery but unapproved in the West. Here is how it got from a Moscow lab in 1991 to today's grey market.
Ipamorelin history: discovery to today
Ipamorelin was first characterised at Novo Nordisk in 1998. Here is the research timeline and why no approved medicine followed.